Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug–drug interaction studies

被引：0
|
作者：
Shuying Yang
Misba Beerahee
机构：
[1] GlaxoSmithKline,Clinical Pharmacology Modelling and Simulation, Research & Development
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Clinical trial simulation population pharmacokinetic analysis; Drug–drug interaction; Sample size; Power;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 233
页数：8
相关论文
共 50 条
  • [31] APPLICATION OF PHARMACOKINETIC DRUG INTERACTION BETWEEN DILTIAZEM AND TACROLIMUS IN CLINICAL RENAL TRANSPLANTATION
    Lim, T. S.
    Lou, H. X.
    Vathsala, A.
    NEPHROLOGY, 2005, 10 : A212 - A212
  • [32] Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam
    Zhou, D.
    Lu, Z.
    Sunzel, M.
    Xu, H.
    Al-Huniti, N.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (04) : 404 - 410
  • [33] Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials
    Gueorguieva, Ivelina
    Jackson, Kimberley
    Wrighton, Steven A.
    Sinha, Vikram P.
    Chien, Jenny Y.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (04) : 523 - 536
  • [34] Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
    Perrier, Jeremy
    Gualano, Virginie
    Helmer, Eric
    Namour, Florence
    Lukacova, Viera
    Taneja, Amit
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (11): : 2222 - 2235
  • [35] Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model
    Chiang, Manting
    Sychterz, Caroline
    Gaohua, Lu
    Perera, Vidya
    Gretler, Daniel D.
    Florea, Victoria
    Merali, Samira
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (11): : 1275 - 1282
  • [36] A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies
    Shinha, Kenta
    Nihei, Wataru
    Ono, Tatsuto
    Nakazato, Ryota
    Kimura, Hiroshi
    BIOMICROFLUIDICS, 2020, 14 (04)
  • [37] Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring
    Brocks, Dion
    Hamdy, Dalia
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2020, 15 (06) : 503 - 514
  • [38] PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
    Burnett, J.
    Sychterz, C.
    Zhu, Y.
    Shakeel, F.
    Dingley, K.
    Chen, W.
    Rajadhyaksha, P.
    Shahane, A.
    Wang, X.
    Gaohua, L.
    Lamba, M.
    Gaudy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S108 - S108
  • [39] Design of a Drug-Drug Interaction Study of Vincristine With Azole Antifungals in Pediatric Cancer Patients Using Clinical Trial Simulation
    van Hasselt, J. G. Coen
    van Eijkelenburg, Natasha K. A.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (12) : 2223 - 2229
  • [40] Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized'' animal models
    Jaiswal, Swati
    Sharma, Abhisheak
    Shukla, Mahendra
    Vaghasiya, Kalpesh
    Rangaraj, Nagarjun
    Lal, Jawahar
    DRUG METABOLISM REVIEWS, 2014, 46 (04) : 475 - 493
12345